COHERUS BIOSCIENCES INC. - COMMON STOCK

Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)

23 Dec 2022 23:01:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update

08 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022

01 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab in Combination with Chemotherapy as First-Line Treatment for Non-Small Cell Lung Cancer, in the Journal of Clinical Oncology

12 Oct 2022 06:30:00 By Nasdaq GlobeNewswire

Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022

19 Sep 2022 06:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference

12 Sep 2022 07:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

29 Aug 2022 19:49:11 By Nasdaq GlobeNewswire

Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update

04 Aug 2022 15:01:01 By Nasdaq GlobeNewswire

FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity

02 Aug 2022 18:15:15 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

01 Aug 2022 22:15:00 By Nasdaq GlobeNewswire

Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022

28 Jul 2022 15:01:00 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma

06 Jul 2022 07:00:01 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

22 Jun 2022 15:30:00 By Nasdaq GlobeNewswire

Coherus BioSciences Appoints Dr. Jill O’Donnell-Tormey to its Board of Directors

11 May 2022 17:00:00 By Nasdaq GlobeNewswire

Coherus BioSciences Management to Present at Upcoming Investor Conferences

10 May 2022 07:45:00 By Nasdaq GlobeNewswire

Coherus BioSciences Reports First Quarter 2022 Results

05 May 2022 15:01:01 By Nasdaq GlobeNewswire

Coherus BioSciences Appoints Charlie Newton to Board of Directors

05 May 2022 07:31:00 By Nasdaq GlobeNewswire

Coherus BioSciences Announces New Employment Inducement Grants

03 May 2022 20:44:59 By Nasdaq GlobeNewswire

Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA

02 May 2022 06:00:01 By Nasdaq GlobeNewswire

CORRECTION - Coherus BioSciences to Report First Quarter 2022 Financial Results on May 5th, 2022

29 Apr 2022 15:01:00 By Nasdaq GlobeNewswire